## FORM 4

(Print or Type Responses)

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	'AL
OMB Number:	3235-0287
Estimated average burd	den
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

DALESANDRO MARGARET			Skye Bioscience, Inc. [SKYE]					(Check all applicable)  _X_ Director							
	E BIOSC	(First) IENCE, INC., 1 SUITE 100	(Middle) 1250 EL		e of Earli 4/2021	liest Tra	nsact	tion (Montl	/Day/Year)		Officer (give ti	le below)	Other (	specify below)	
<u>'</u>				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)  Table I - Non-Derivative Securities Acqui					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person aired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye		Exe any		Date, if	(Instr. 8)		4. Securities (A) or Dispos (Instr. 3, 4 an	ed of (D)	of (D) Owned Followin Transaction(s)		O Fe	wnership orm:	Beneficial		
				(Mc	onth/Day/	// Y ear)	Co	ode V		or O) Price	(Instr. 3 and 4)		(I	Indirect (	Ownership Instr. 4)
Reminder:	report on a s	1						this	orm are not i	equired to	collection of in respond unles			n SEC 14	174 (9-02)
Reminder:	report on a c		Table :	II - Deri	ivative So	Securitie	es Ac	this		equired to IB control	respond unles number.			n SEC 14	174 (9-02)
1. Title of	2. Conversion	3. Transaction	3A. Deemed Execution Date, if	4. Transac Code	5. Notion Der Secon I (D)	Number erivative curities equired (Dispose	of  (A) ed of	equired, Dits, options. 6. Date Expiration (Month/D	orm are not in the properties of the convertible seems of the convertible and the conv	equired to IB control eneficially ( curities) 7. Title an	respond unles number. Owned d Amount of g Securities	8. Price of	9. Number of Derivative Securities Beneficially Owned Following	10. Ownershi Form of Derivative Security: Direct (D	11. Natu p of Indire Benefici Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction	3A. Deemed Execution Date, if any	4. Transac Code	tion Sec Sec Sec Or I (D) (Ins	Number rivative curities equired (Dispose	of  (A) ed of	equired, Dits, options. 6. Date Expiration (Month/D	orm are not in intly valid ON sposed of, or B convertible seercisable and Date by/Year)	eneficially (curities)  7. Title an Underlyin	respond unles number. Owned d Amount of g Securities	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned	10. Ownershi Form of Derivative Security: Direct (D or Indirec	11. Natu p of Indire Benefici Ownersh (Instr. 4)

### **Reporting Owners**

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
DALESANDRO MARGARET C/O SKYE BIOSCIENCE, INC. 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO, CA 92130	X				

#### **Signatures**

/s/ Margaret Dalesandro	09/16/2021
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Option shall be exercisable for a price of \$0.12 per Option Share in twelve equal monthly installments such that all the Option Shares shall vest in twelve months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.